VIVLODEX Gives Patients With Osteoarthritis (OA) Pain a Low-dose NSAID Treatment Option

To learn more about nonsteroidal anti-inflammatory drugs (NSAIDs) and why low-dose NSAIDs are an important development in treating OA pain, click these links:

VIVLODEX 5 mg: The lowest FDA-approved dose of meloxicam available

VIVLODEX is the first US Food and Drug Administration (FDA)-approved low-dose SoluMatrix® meloxicam for OA pain.

VIVLODEX: A Low-Dose NSAID Option for Management of OA Pain

Iroko Pharmaceuticals, LLC, created VIVLODEX with OA patients in mind:

  • VIVLODEX is the first low-dose SoluMatrix® meloxicam – a trusted and commonly used NSAID for OA pain
  • Low-dose SoluMatrix® NSAIDs were developed by Iroko to align with recommendations from FDA, medical organizations, and advocacy groups: use the lowest effective NSAID dose for the shortest period of time

In addition to being the first low-dose SoluMatrix® meloxicam available, data show VIVLODEX:

  • Effectively managed OA pain at low doses
  • Was generally well tolerated
VIVLODEX is FDA approved at low 5-mg and 10-mg doses administered once daily for the management of OA pain.

Iroko Pharmaceuticals, LLC, created VIVLODEX with SoluMatrix Fine Particle Technology, an innovative scientific process that creates NSAID drug particles that are approximately 10- to 20-times smaller than their original size.

  • The result: low-dose NSAID pain medicine that is rapidly absorbed by the body
Particle Chart

Original NSAID particles

SoluMatrix® NSAID particles

Eligible* patients
pay as little as
$10

*Terms and Conditions may apply.

Looking for a low-dose NSAID option to manage OA pain?

Ask your doctor about VIVLODEX

NSAIDs and the FDA: 
Warnings and Recommendations

Over the past decade, the FDA has monitored and evaluated the safety of NSAIDs

In 2005, based on new evidence about NSAID risks, the FDA began requiring manufacturers of prescription NSAIDs to include new safety warnings:

  • The boxed warning highlighted the potential for increased risk of serious cardiovascular (CV) events with these drugs and the well-described, serious, and potentially life-threatening gastrointestinal (GI) bleeding associated with their use
  • The FDA specifically recommended taking the lowest effective NSAID dose for the shortest period of time

In July 2015, the FDA strengthened its warning about NSAID use to emphasize that patients taking NSAIDs are at greater risk for heart attack or stroke.

Potential Risks With NSAIDs

The higher the NSAID dose, the higher the risk of serious side effects.

Risk of Heart Problems

NSAID use may:

Increase the chance of heart attack or stroke in people with or without heart disease or risk factors for heart disease

Risk of Stomach and GI Problems

NSAID use may:

Increase the chance of bleeding, ulcers, and tears (perforations) of the esophagus (the tube leading from the mouth to the stomach), stomach, and intestines

Risk of Kidney Problems

NSAID use may:

Increase the chance of kidney problems, including kidney failure and progressive kidney damage

VIVLODEX matters because:

Nearly half of all patients treated for OA pain are treated with an NSAID

Meloxicam, the active ingredient used to make VIVLODEX, is a trusted NSAID physicians have used for years to help patients with OA pain

Although data show meloxicam can help manage OA pain, they also show NSAIDs like meloxicam in high doses can increase the risk of serious stomach problems

The higher the NSAID dose, the higher the risk of serious stomach problems

The FDA recommends that patients take the lowest effective NSAID dose for the shortest period of time.

VIVLODEX 5 mg offers the lowest effective meloxicam dose for managing OA pain.

Looking for a low-dose NSAID option to manage OA pain?

 

Ask your doctor about VIVLODEX

Eligible* patients pay as little as $10.

*Terms and Conditions apply.

Get Your Savings Card